REGENXBIO (NASDAQ:RGNX) Stock Rating Reaffirmed by Wedbush

Wedbush restated their neutral rating on shares of REGENXBIO (NASDAQ:RGNXFree Report) in a report released on Monday, Marketbeat.com reports. The firm currently has a $21.00 price objective on the biotechnology company’s stock.

RGNX has been the subject of several other reports. William Blair restated a neutral rating and set a $21.00 price target (up from $20.00) on shares of REGENXBIO in a report on Tuesday, November 14th. Stifel Nicolaus began coverage on REGENXBIO in a report on Wednesday, November 1st. They set a buy rating and a $35.00 price target for the company. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average target price of $33.71.

Get Our Latest Report on REGENXBIO

REGENXBIO Trading Up 7.1 %

RGNX opened at $17.36 on Monday. The stock has a fifty day simple moving average of $16.40 and a two-hundred day simple moving average of $17.06. REGENXBIO has a 12-month low of $11.83 and a 12-month high of $25.32.

Insiders Place Their Bets

In other REGENXBIO news, CEO Kenneth T. Mills sold 45,000 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $15.18, for a total value of $683,100.00. Following the transaction, the chief executive officer now directly owns 408,035 shares of the company’s stock, valued at $6,193,971.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other REGENXBIO news, insider Steve Pakola sold 17,237 shares of the firm’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $17.39, for a total value of $299,751.43. Following the transaction, the insider now directly owns 107,192 shares of the company’s stock, valued at $1,864,068.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kenneth T. Mills sold 45,000 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $15.18, for a total value of $683,100.00. Following the completion of the transaction, the chief executive officer now directly owns 408,035 shares in the company, valued at $6,193,971.30. The disclosure for this sale can be found here. Over the last three months, insiders have sold 107,237 shares of company stock valued at $1,868,451. Insiders own 13.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Jennison Associates LLC lifted its position in shares of REGENXBIO by 6.5% during the 2nd quarter. Jennison Associates LLC now owns 37,532 shares of the biotechnology company’s stock valued at $750,000 after buying an additional 2,304 shares in the last quarter. Raymond James & Associates lifted its position in shares of REGENXBIO by 405.3% during the 3rd quarter. Raymond James & Associates now owns 100,620 shares of the biotechnology company’s stock valued at $1,656,000 after buying an additional 80,706 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of REGENXBIO by 47.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,540 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 3,379 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in shares of REGENXBIO by 6.4% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 14,539 shares of the biotechnology company’s stock valued at $239,000 after buying an additional 870 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of REGENXBIO by 3.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 366,958 shares of the biotechnology company’s stock valued at $7,335,000 after buying an additional 12,075 shares in the last quarter. 88.80% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Company Profile

(Get Free Report)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

Recommended Stories

Analyst Recommendations for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.